TrialClinical epigenetics2025

HCV patients with residual fibrosis after DAA treatment re-establish their epigenetic signature after prolonged-release pirfenidone: MINERVA study.

Eira Cerda-Reyes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.